Cell & Gene Therapy Market - Global Forecast 2025-2032

The cell and gene therapy market is rapidly evolving, driven by cutting-edge scientific, regulatory, and commercial developments. Senior healthcare, biotech, and life sciences leaders require an accurate, actionable resource that captures the complexity and opportunity across this dynamic landscape.

Market Snapshot: Cell and Gene Therapy Market Growth Trajectory

The cell and gene therapy market expanded from USD 16.65 billion in 2024 to USD 19.47 billion in 2025. Projected to sustain a CAGR of 19.95%, it is forecast to reach USD 71.38 billion by 2032, underscoring robust commercialization and adoption momentum globally. This surge reflects investments in innovative treatments targeting genetic, metabolic, oncologic, and neurological conditions, as well as the increasing ability to scale manufacturing and regulatory processes across regions. The primary keyword, "cell and gene therapy market," positions this segment as a key driver for life sciences transformation and long-term value creation.

Scope & Segmentation of the Cell and Gene Therapy Market

This comprehensive market report delivers structured insight across technologies, applications, and end users. Market segmentation covers:

• Therapy Type: Cell therapies, including stem cell and T cell (such as CAR T and TCR-based) approaches, as well as gene therapies (ex vivo and in vivo).
• Delivery Method: Intramuscular and intravenous routes used for diverse clinical and research applications.
• Therapeutic Areas: Cardiovascular (congestive heart failure, ischemic heart disease), metabolic disorders (diabetes, obesity), neurological disorders (Alzheimer's, Huntington's, multiple sclerosis, Parkinson's, spinal cord injuries), oncology (hematological malignancies, lymphomas, solid tumors), and ophthalmology.
• Application: Clinical—focusing on disease prevention and treatment—and research and development initiatives.
• End User: Academic research institutes, private laboratories, universities, hospitals, and clinics.
• Regional Coverage: Americas (North America, Latin America), Europe, Middle East & Africa (Europe, Middle East, Africa), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Southeast Asia).
• Leading Companies: In-depth analysis includes major industry players such as AbbVie, Alnylam Pharmaceuticals, Amgen, Biogen, CRISPR Therapeutics, Gilead, Intellia, Johnson & Johnson, Novartis, Pfizer, Thermo Fisher, Vertex, among others.

Key Takeaways for Senior Decision-Makers

• Scientific advances in vector engineering, platform automation, and cell processing are facilitating safer, more effective therapies with streamlined regulatory review.
• Tariff changes introduced in the United States in 2025 have increased supply chain scrutiny and shifted clinical trial site selection, favoring regions with established capabilities or more advantageous trade agreements.
• Collaborative innovation, including cross-sector consortiums and pharmaceutical-biotech alliances, is accelerating knowledge transfer and platform integration for both cell and gene therapies.
• Regional market entry strategies must account for local regulatory harmonization, reimbursement frameworks, and domestic manufacturing partnerships, especially across Asia-Pacific and EMEA territories.
• End users benefit from expanded access to both autologous and allogeneic modalities, with digital health platforms enhancing long-term monitoring and patient support programs.

Tariff Impact on the Cell and Gene Therapy Market

Recent U.S. tariffs targeting raw materials and production equipment have significantly affected manufacturer sourcing decisions and production economics. These adjustments have led to strategic evaluation of alternative suppliers and expanded local manufacturing footprints. International commercialization strategies now also emphasize onshore production, tariff-friendly jurisdiction partnerships, and inventory management optimization to minimize risks and maintain therapy availability. Clinical trial logistics are likewise adapting, resulting in increased adoption of decentralized models for site and patient resource management.

Methodology & Data Sources

This report employs a robust, multi-faceted research methodology. It integrates expert interviews with industry leaders from biotechnology and manufacturing firms, clinical practitioners, regulatory specialists, and payers. Secondary research includes analysis of peer-reviewed publications, proprietary databases, regulatory documentation, and recent conference proceedings. Data triangulation ensures reliability and informs actionable insights for strategic planning.

Why This Report Matters: Strategic Value for Industry Leaders

• Delivers segment-specific intelligence, enabling effective R&D investment allocation and targeted commercialization efforts for organizations seeking competitive advantage.
• Highlights regulatory, technological, and supply chain dynamics essential for expanding geographic reach and strengthening global partnerships.
• Supports informed decision-making for C-suite leaders tasked with navigating evolving regulatory hurdles and maximizing opportunity within specialized therapeutic domains.

Conclusion: Outlook for the Cell and Gene Therapy Market

The cell and gene therapy market’s continued development is shaped by regulatory agility, technological advancement, and global stakeholder collaboration. Organizations adopting adaptable, data-driven strategies will be best equipped to succeed in this complex, rapidly expanding sector.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.